Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 6

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 (the “Company,”
“Mosaic,” “we,” “us,” or “our”) is a corporation organized under Delaware law on March
24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the
treatment of cancer. We have historically advanced early-stage product candidate and we are pursuing new product candidates and platforms
to expand our pipeline based on our understanding of immunotherapies and our license agreements with University of California San Diego.

The Company has two inactive wholly owned subsidiaries:
Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions
Group, Inc.

Going Concern and Management’s Plans

The accompanying unaudited condensed consolidated
financial statements have been prepared assuming the Company will continue as a going concern. At June 30, 2025, the Company had cash
and cash equivalents of $53,583 and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent
on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions, that our
cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date
of this Quarterly Report on Form 10-Q.

There are a number of uncertainties associated with
our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the
continuation of disruptions caused by COVID-19 or other variants or pandemics, broad-based inflation, and various economic indicators
that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision
to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any
additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital
will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then
existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.

    2.
    Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated
financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly
reports on Form 10-Q and do not include all of the information and footnotes required